Hysteroscopic biopsy compared with endometrial curettage to assess the preoperative rate of atypical hyperplasia underestimating endometrial carcinoma
Archives of Gynecology and Obstetrics · 2023
DOI: 10.1007/s00404-023-07060-2 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Archives of Gynecology and Obstetrics, 2023. Verfasst von Giancarlo Garuti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Obstetrics and Gynecology Department, Hospital of Lodi, Via Savoia 1, 26900, Lodi, Italy. giancarlo.garuti@tiscali.it. Hauptthemen laut MEDLINE: Endometrial Hyperplasia, Endometrial Neoplasms, Precancerous Conditions. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To evaluate the rate of atypical hyperplasia (AH) underestimating endometrial cancer (EC) comparing endometrial biopsy (EB) accomplished by hysteroscopic biopsy with dilatation and curettage (D&C). Second, to compare the two techniques to foresee EC grading. METHODS: This trial was based on the findings of two Gynecological Departments within the same Public Utility, sharing pathological service and database but routinely performing EB under hysteroscopic visualization (group A) or hysteroscopy followed by D&C (group B). We retrieved the clinical data of patients showing EC on hysterectomy throughout a 10-year period. The accuracy of hysteroscopic-view diagnosis and EB pathology were compared, having the pathologic findings of hysterectomy as reference. RESULTS: A total of 161 patients met the inclusion criteria. Among these, 109 and 52 were included in groups A and B, respectively. In group A, 32.1% of patients underwent EB in an out-patient setting. To foresee EC, hysteroscopic view showed a sensitivity of 82.5% and 70.2% in groups A and B, respectively (P = 0.019). An underestimation of EC diagnosed as AH on EB was found in 20 patients (12.4%). Among these, 18 (16.5%) and 2 (3.8%) were included in groups A and B, respectively (P = 0.022). In group A, a fault diagnosis of AH resulted higher when EB was performed as out-patient setting (P = 0.006). EB allowed the grading of EC in 73.3% and 90.3% of patients in groups A and B, respectively. The agreement was 73.7% and 85.1%, leading to moderate (κ = 0.56) and good (κ = 0.77) "κ" coefficient of concordance for groups A and B, respectively. CONCLUSIONS: EB performed by D&C lowers the rate of AH underestimating concurrent EC and improves the grading agreement when compared with hysteroscopic sampling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Obstetrics and Gynecology Department, Hospital of Lodi, Via Savoia 1, 26900, Lodi, Italy. giancarlo.garuti@tiscali.it.
- Medical Oncology Department, Hospital of Lodi, Via Savoia 1, 26900, Lodi, Italy.
- Obstetrics and Gynecology Department, Hospital of Lodi, Via Savoia 1, 26900, Lodi, Italy.
- Department of Pathology, Via Savoia 1, 26900, Lodi, Italy.
ORCID-Profile: Giancarlo Garuti
Zitieren
APA
Garuti, G., Sagrada, P. F., Frigoli, A., Fornaciari, O., Finco, A., Mirra, M., & Soligo, M. (2023). Hysteroscopic biopsy compared with endometrial curettage to assess the preoperative rate of atypical hyperplasia underestimating endometrial carcinoma. Archives of Gynecology and Obstetrics. https://doi.org/10.1007/s00404-023-07060-2
Vancouver
Garuti G, Sagrada PF, Frigoli A, Fornaciari O, Finco A, Mirra M, et al. Hysteroscopic biopsy compared with endometrial curettage to assess the preoperative rate of atypical hyperplasia underestimating endometrial carcinoma. Archives of Gynecology and Obstetrics. 2023. doi:10.1007/s00404-023-07060-2
BibTeX
@article{Garuti2023,
author = {Garuti, Giancarlo and Sagrada, Paola Francesca and Frigoli, Antonella and Fornaciari, Ottavia and Finco, Andrea and Mirra, Maurizio and Soligo, Marco},
title = {Hysteroscopic biopsy compared with endometrial curettage to assess the preoperative rate of atypical hyperplasia underestimating endometrial carcinoma},
journal = {Archives of Gynecology and Obstetrics},
year = {2023},
doi = {10.1007/s00404-023-07060-2}
}
EUVIMED